Portfolio company
Elevian
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops regenerative medicines targeting the GDF11 pathway to treat stroke and age-related diseases for patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Altos Labs
This biotechnology company develops cellular rejuvenation therapies to restore cell health and reverse diseases for patients with chronic illnesses and age-related disabilities.
NewLimit
This biotechnology company develops epigenetic reprogramming medicines to restore cellular function and treat age-related diseases for patients.
Rejuveron Life Sciences
This clinical-stage biotechnology company develops regenerative medicines and small-molecule therapies for patients with age-related diseases to improve healthspan and longevity.
Souvien Therapeutics
This biotechnology company develops therapeutic agents targeting epigenetic mechanisms to treat neurodegenerative diseases for patients with age-related conditions like dementia.
clock.bio
This biotechnology company develops regenerative therapies for patients with age-related diseases by using gene-editing technology to decode cellular rejuvenation programs in human stem cells.
Elastrin
This biotechnology company develops nanoparticle therapies targeting damaged elastin to reverse tissue calcification for patients with cardiovascular and age-related diseases.
Juvena Therapeutics
This biotechnology company develops protein-based regenerative medicines for patients with chronic muscle and metabolic diseases.
Life Biosciences
This biotechnology company develops cellular rejuvenation therapies using epigenetic restoration to treat age-related diseases, such as optic neuropathies, for patients with chronic conditions.
